Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of FG-3019, a
therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth
factor (CTGF). CTGF triggers the production of collagen and fibronectin, which cause scarring
and thickening of the lungs. Approximately 18 to 27 males and females, 21 to 80 years of age
with a diagnosis of idiopathic pulmonary fibrosis (IPF) will be enrolled in this study. The
duration of the study is approximately one month, during which patients will receive a single
infusion of FG-3019. In addition, there will be two follow-up visits 6 and 12 months after
receiving the study drug.